ClinicalTrials.gg
CompletedNCT02046369IlluminateUpdated Dec 20, 2017Results posted

Lurasidone Pediatric Bipolar Study

A Phase 3 interventional study of Lurasidone and Placebo in Bipolar I Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 66 sites in 11 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-12-20.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.

Enrollment
8th of 17
350 · median 348
Started
2014
with 2 others
Phase 3
11 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
8 of 17
Sumitomo Pharma America, Inc.

Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 11th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lurasidone in Bipolar Disorder, or all of them as a file.
02

Study summary

A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression

Read the detailed description

This is a randomized, parallel, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of flexibly dosed lurasidone (20 - 80 mg/day) for 6 weeks compared with placebo in children and adolescent subjects with depression associated with Bipolar I Disorder (bipolar depression).

03

Conditions studied

  • Bipolar I Depression

Browse trials for

Keywords

  • Lurasidone, Latuda, Bipolar Depression
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' adherence to the study procedures must be obtained for subjects who are not emancipated. If emancipated, subjects must provide written informed consent. In accordance with Institutional Review Board (IRB) requirements, the subject will complete an informed assent prior to study participation.

    • Male or female subjects 10 to 17 years of age, inclusive with bipolar I disorder, most recent episode depressed, with or without rapid cycling disease course (≥ 4 episodes of mood disturbance but \< 8 episodes in the previous 12 months) and without psychotic features (diagnosed by criteria, and confirmation of the bipolar I disorder diagnosis by an adequately trained clinician at the time of screening, by means of the Schedule for Affective Disorders and Schizophrenia for School-age Children [K-SADS-PL]). Note: The current episode of major depression associated with bipolar I disorder must be confirmed by the investigator and noted in the source records.
    • Subject has a lifetime history of at least one manic episode. A reliable informant (eg, family member or caregiver) or medical records must be able to confirm this history.
    • Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration.
    • CDRS-R score ≥ 45 at screening and Baseline.
    • YMRS score ≤ 15 (with YMRS Item 1 [elevated mood] score ≤ 2) at screening and Baseline.
    • Within 3rd to 97th percentile for gender specific -for-age growth charts from the World Health Organization (WHO) growth charts
    • In good physical health on the basis of medical history, physical examination, and laboratory screening.
    • Females who participate in this study:

      • are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
      • practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-
      • are sexually active and willing to use a medically effective method of (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
    • Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
    • In the judgment of the investigator, the subject is able to swallow the size and number of study drug tablets specified per protocol
    • Willing and able to adhere to protocol-specified meal requirements during dosing.
    • Subjects may have a lifetime diagnosis of ADHD. If a subject is taking psychostimulants for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. This must be confirmed by the investigator and noted in the source records.

Exclusion criteria

Exclusion Criteria:

  • Has an Axis I or Axis II ( or any DSM-5) diagnosis other than bipolar I disorder that has been the primary focus of treatment within 3 months of screening.
  • Subject has been hospitalized for a bipolar manic or mixed episode within the 30 days prior to randomization.
  • Has a history or current diagnosis of intellectual disability, autism spectrum disorder, neuroleptic malignant syndrome, or any neurologic disorder, or severe head trauma.
  • Lifetime history of (HIV) positive or acquired immune deficiency syndrome (AIDS), or history of or C.
  • Any of the following:
  • Documented history of chromosomal disorder with developmental impairment (ie, trisomy chromosome 21; 22q11 deletion syndrome).
  • Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood - eg, Duchenne muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders. In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.
  • CDRS-R total score > 85 at screening or Baseline
  • Demonstrates a decrease (improvement) of ≥ 25% in the CDRS-R adjusted total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline.
  • Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
  • Lifetime history of electroconvulsive therapy (ECT).
  • Resistant to antipsychotic treatment based on at least two prior adequate trials (ie, adequate dose and duration) of an antipsychotic agent within the current episode of depression, or subject has a history of non-response to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode.
  • neurological, metabolic (including Type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.
  • Has a history of \< 5 years prior to signing the .
  • Clinically significant finding(s) on physical examination determined by the investigator to pose a health concern to the subject while on study.
  • Clinically relevant abnormal laboratory values or abnormal vital sign values/findings.
  • A history or presence of abnormal , which in the investigator's opinion is clinically significant. Abnormal screening ECGs will be centrally over-read, and eligibility will be determined based on the over-read.
  • Presence or history (within the last year) of a medical or surgical condition (eg, gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
  • Clinically significant substance abuse disorder (with the exception of caffeine or tobacco) based on DSM-5 criteria within the last 6 months prior to screening.
  • Positive test results at screening or Baseline for:

    1. Urine drugs of abuse (including amphetamines/methamphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine, and cannabinoids). A positive test for amphetamines/methamphetamines, barbiturates, opioids, or benzodiazepines may not result in exclusion of subjects if the investigator determines that the positive test is as a result of taking prescription medicine(s) as prescribed. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the investigator will evaluate the subject's ability to abstain from prohibited substances during the study. If in the investigator's clinical judgment the subject will abstain, the subject may be enrolled after consultation with the Medical Monitor.
    2. Pregnancy test.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Participated in another interventional clinical trial or receiving an product within 30 days prior to screening.
  • Donation of whole blood within 60 days prior to randomization.
  • Known history or presence of clinically significant intolerance to any antipsychotic medications including but not limited to angioedema, serotonin or neuroleptic malignant syndromes.
  • Clinically relevant history of drug to lurasidone or any components in the formulation.
  • Use of concomitant medications that consistently prolong the /QTc interval within 28 days prior to randomization.
  • Received depot neuroleptics unless the last injection was at least 1 month or 1 treatment cycle prior to screening, whichever is longer.
  • Received treatment with antidepressants, atomoxetine or alpha 2 agonists (eg, guanfacine) within 3 days prior to randomization, fluoxetine hydrochloride within 21 days of randomization, monoamine oxidase (MAO) inhibitor within 28 days of randomization, or clozapine within 120 days of randomization.
  • Use of all psychotropic medications prior to randomization with the exception of those medications explicitly permitted within 3 days prior to randomization (7 days prior to randomization for aripiprazole).
  • Has a prolactin concentration ≥ 100 ng/mL at screening, or has a history of pituitary adenoma.
  • At screening or Baseline the subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the C-SSRS or has a score of 7 on item 13, Suicidal Ideation, on the CDRS-R.
  • Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property during the study. Subject has a history of one or more serious suicide attempts (based on the investigator's judgment) in the 3 months prior to screening. Subjects determined to be at risk of suicide or injury, as assessed by the investigator at screening, will be referred for further psychiatric evaluation.
  • Adhering to a special diet for the 28 days prior to drug administration (eg, liquid, protein, raw food diet).
  • Subject is planning to move during the study, is chronically homeless, or is unable to attend all planned study visits. The Medical Monitor will be consulted for individual cases, as needed.
  • Subject with newly diagnosed Type 2 diabetes during screening or subject is on injectable medication for the treatment of Type 2 diabetes. A subject with Type 2 diabetes is eligible for study inclusion if considered clinically stable, which is defined as:

    • Random (non-fasting) screening glucose is \< 200 mg/dl (11.1 mmol/L); and If ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state. Retested fasted value cannot be ≥ 126 mg/dL.
    • ≤ 6.5%; and
  • If a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.
  • Subject has required hospitalization for diabetes or related complications in the past 12 months.
  • The use of concomitant medications that are potent inducers or inhibitors of the cytochrome P450 (CYP) 3A4 enzyme system during the trial (from signing informed consent until follow-up).
  • Clinically significant orthostatic hypotension (ie, a drop in systolic blood pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or more within 4 minutes of standing up).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    Luradisone

    Luradisone 20- 80 mg administered once daily

    Drug: Lurasidone

  • Placebo comparator
    Placebo

    Placebo administered once daily

    Drug: Placebo

Interventions

  • Lurasidone flexibly dosed 20-80 mg once daily

    Also known as: Latuda

  • DrugPlacebo

    Placebo Comparator once daily

06

What researchers measure

Primary outcomes

  1. Change in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score as Compared to Placebo From Double-Blind Baseline to Week 6 (Day 43) Baseline

    CDRS-R total score: changes from baseline over time - mixed model for repeated measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness. The primary efficacy endpoint will be assessed between the placebo and treatment group.

    Time frame: baseline, Week 6

Secondary outcomes

  1. Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Score as Compared to Placebo.

    PARS score: changes from baseline over time - mixed model for repeated measures-LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures.The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6-17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. The PAR total score over all 7 questions ranges in value from 0 to 35.

    Time frame: baseline and week 6

  2. Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Score as Compared to Placebo.

    PQ-LES-Q percentage maximum possible score: changes from baseline over time - mixed model for repeated measures LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures

    Time frame: baseline

  3. Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score as Compared to Placebo.

    CGAS Score: changes from baseline over time - mixed model for repeated measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures

    Time frame: baseline and week 6

  4. Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Score as Compared to Placebo.

    ADHD-RS total score: changes from baseline over time -ANCOVA-LS Mean and SE for change from baseline are based on ANCOVA. The Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:% Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score),where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

    Time frame: baseline and week 6

  5. Change From Baseline in Clinical Global Impressions-Bipolar-Severity (CGI-BP-S) Depression Score

    Change from baseline in Clinical Global Impressions-Bipolar-Severity (CGI-BP-S) depression score changes from baseline over time - mixed model for repeated measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures.The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.

    Time frame: baseline and week 6

07

Results

Posted Dec 20, 2017

Participant flow

Participant flow — Overall Study
MilestoneLuradisonePlacebo
Started176174
Completed162156
Not completed1418
Withdrew: Adverse event33
Withdrew: Lack of efficacy33
Withdrew: Lost to follow-up33
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject36
Withdrew: Never received study drug01
Withdrew: Non compliance10

Outcome measures

PrimaryChange in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score as Compared to Placebo From Double-Blind Baseline to Week 6 (Day 43) Baseline

CDRS-R total score: changes from baseline over time - mixed model for repeated measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness. The primary efficacy endpoint will be assessed between the placebo and treatment group.

Time frame:
baseline, Week 6
Reported as:
Least squares mean · units on a scale
Change in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score as Compared to Placebo From Double-Blind Baseline to Week 6 (Day 43) Baseline
units on a scaleLuradisonePlacebo
baseline59.2 ± 8.2458.6 ± 8.26
week 6-21.0 ± 1.06-15.3 ± 1.08
Statistical analysis
  • Luradisone vs Placebo · LS mean differnece (SE) · p = <0.0001 · Ls mean differnce (se): -5.7 · 95% CI -8.4 to -3.0
SecondaryChange From Baseline in Pediatric Anxiety Rating Scale (PARS) Score as Compared to Placebo.

PARS score: changes from baseline over time - mixed model for repeated measures-LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures.The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6-17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. The PAR total score over all 7 questions ranges in value from 0 to 35.

Time frame:
baseline and week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Score as Compared to Placebo.
units on a scaleLuradisonePlacebo
baseline10.9 ± 7.7211.5 ± 7.60
week 6-3.4 ± 0.44-2.3 ± 0.45
Statistical analysis
  • Luradisone vs Placebo · LS mean differnece (SE) · p = 0.0385 · Ls mean differnce (se): -1.1 · 95% CI -2.2 to -0.1
SecondaryChange From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Score as Compared to Placebo.

PQ-LES-Q percentage maximum possible score: changes from baseline over time - mixed model for repeated measures LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures

Time frame:
baseline
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Score as Compared to Placebo.
units on a scaleLuradisonePlacebo
baseline49.6 ± 15.4949.7 ± 17.31
week 611.8 ± 1.107.9 ± 1.13
Statistical analysis
  • Luradisone vs Placebo · LS mean differnece (SE) · p = 0.0044 · Ls mean differnce (se): 3.9 · 95% CI 1.2 to 6.5
SecondaryChange From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score as Compared to Placebo.

CGAS Score: changes from baseline over time - mixed model for repeated measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures

Time frame:
baseline and week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score as Compared to Placebo.
units on a scaleLuradisonePlacebo
baseline48.8 ± 8.7349.5 ± 6.99
week 614.0 ± 0.969.3 ± 0.99
Statistical analysis
  • Luradisone vs Placebo · LS mean differnece (SE) · p = <0.0001 · Ls mean differnce (se): 4.7 · 95% CI 2.4 to 7.0
SecondaryChange From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Score as Compared to Placebo.

ADHD-RS total score: changes from baseline over time -ANCOVA-LS Mean and SE for change from baseline are based on ANCOVA. The Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:% Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score),where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.

Time frame:
baseline and week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Score as Compared to Placebo.
units on a scaleLuradisonePlacebo
baseline11.8 ± 10.8512.3 ± 11.62
week 6-2.6 ± 7.26-2.0 ± 7.61
Statistical analysis
  • Luradisone vs Placebo · ANCOVA · p = 0.3715 · Ls mean differnce (se): -0.7 · 95% CI -2.2 to 0.8
SecondaryChange From Baseline in Clinical Global Impressions-Bipolar-Severity (CGI-BP-S) Depression Score

Change from baseline in Clinical Global Impressions-Bipolar-Severity (CGI-BP-S) depression score changes from baseline over time - mixed model for repeated measures. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures.The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.

Time frame:
baseline and week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Global Impressions-Bipolar-Severity (CGI-BP-S) Depression Score
units on a scaleLuradisonePlacebo
baseline4.6 ± 0.654.5 ± 0.57
week 6-1.49 ± 0.085-1.05 ± 0.087
Statistical analysis
  • Luradisone vs Placebo · LS mean differnece (SE) · p = <0.0001 (LS mean difference, and the associated 95% CI and p-value for change from baseline are based on Mixed Model for Repeated Measures (MMRM).) · Ls mean differnce (se): -0.44 · 95% CI -0.66 to -0.22

Adverse events

Collected over Through study completion. Treatment emergent adverse event (TEAE) is defined as an AE with a start date on or after the date of first does through 7 days after study drug discontinuation (14 days for serious adverse events and deaths) for subjects who complete the double blind study but do not enter the extension study or early discontinue during the double blind study), or through the last study day of the double blind period for subjects continuing into the extension study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Luradisone—2/175 (1.1%)112/175 (64%)
Placebo—4/172 (2.3%)75/172 (43.6%)
Most frequent serious events
Most frequent serious events
EventLuradisonePlacebo
Bipolar I disorderPsychiatric disorders1/1751/172
depressionPsychiatric disorders0/1751/172
psychotic disorderPsychiatric disorders0/1751/172
abortion spontaneousPregnancy, puerperium and perinatal conditions0/1751/172
humerus fractureInjury, poisoning and procedural complications1/1750/172
Most frequent other events
Most frequent other events
EventLuradisonePlacebo
nauseaGastrointestinal disorders28/17510/172
headacheNervous system disorders25/17526/172
somnolenceNervous system disorders16/1758/172
weight increasedInvestigations12/1753/172
vomitingGastrointestinal disorders11/1756/172
nasopharyngitisInfections and infestations7/17510/172
dizzinessNervous system disorders10/1758/172
insomniaPsychiatric disorders9/1754/172

Baseline characteristics

Baseline analysis was done on the safety population, which has 347 subjects

Age, Categorical
Age, Categorical(Participants)LuradisonePlaceboTotal
<=18 years175172347
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)LuradisonePlaceboTotal
Mean14.2 ± 2.1814.3 ± 2.0114.2 ± 2.11
Sex: Female, Male
Sex: Female, Male(Participants)LuradisonePlaceboTotal
Female8783170
Male8889177
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LuradisonePlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino175172347
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LuradisonePlaceboTotal
American Indian or Alaska Native202
Asian7411
Native Hawaiian or Other Pacific Islander000
Black or African American162036
White135125260
More than one race152338
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)LuradisonePlaceboTotal
Colombia7714
South Korea437
Hungary5510
United States7575150
Philippines202
Ukraine333366
Poland235
Mexico161733
Bulgaria9817
France101
Russia212142
Psychiatric History
Psychiatric History(years)LuradisonePlaceboTotal
Mean12.44 ± 2.79012.17 ± 2.68012.30 ± 2.735
Bipolar I disorder history
Bipolar I disorder history(Participants)LuradisonePlaceboTotal
Without rapid cycling (0-3 cycles past 12 months149147296
Without rapid cycling(4-7 cycles past 12 months262450
With 8 or more cycles within past 12 months011
08

Study locations

66 sites
  • Harmonex Neuroscience Research
    Dothan, Alabama 36303, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Hartford Hospital
    Hartford, Connecticut 06106, United States
  • Sarkis Clinical Trials - Parent
    Gainesville, Florida 32607, United States
  • APG Research, LLC
    Orlando, Florida 32803, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Attalla Consultants, LLC
    Smyrna, Georgia 30080, United States
  • Capstone Clinical Research, Inc.
    Libertyville, Illinois 60048, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70629, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Neurobehavioral Medicine Group, PLLC
    Bloomfield Hills, Michigan 48302, United States
  • St. Charles Psychiatric Associates
    Saint Charles, Missouri 63301, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
  • North Shore/Long Island Jewish PRIME
    Glen Oaks, New York 11004, United States
  • Bioscience Research, LLC
    Mount Kisco, New York 10549, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219-0516, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Cutting Edge Research of Enid
    Oklahoma City, Oklahoma 73116, United States
  • Research Strategies of Memphis, LLC
    Memphis, Tennessee 38119, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75228, United States
  • Family Psychiatry of The Woodlands, P.A.
    The Woodlands, Texas 77381, United States
  • Ericksen Research & Development, LLC
    Clinton, Utah 84015, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Clinical Research Partners, LLC
    Petersburg, Virginia 23805, United States
  • Pacific Institute Of Medical Sciences
    Bothell, Washington 98011, United States
  • MHC - Ruse, EOOD
    Ruse, 7003, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • DCC "Mladost M" - Varna, OOD
    Varna, 9020, Bulgaria
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA
    Barranquilla, Colombia
  • Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
    Bogota, 00000, Colombia
  • Hôpitaux Pédiatriques de Nice CHU-Lenval
    Nice, Alpes Maritimes 06200, France
  • CHU Nantes - Hôpital Mère-Enfant
    Nantes Cedex 1, 44093, France
  • Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert
    Budapest, 1021, Hungary
  • Bekes Megyei Pandy Kalman Korhaz
    Gyula, 5700, Hungary
  • Chonbuk National University Hospital
    Jeonju, Jeollabuk-do 561-712, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, Jeollanam-do 501-757, Korea, Republic of
  • Inha University Hospital
    Incheon, 400-711, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, 463-707, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110774, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 120-752, Korea, Republic of
  • Accelerium S. de R.L. de C.V.
    Monterrey, Nuevo León 64000, Mexico
  • Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
    Culiacan, 80020, Mexico
  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
    Durango, 34000, Mexico
  • Instituto de Informacion de Investigacion en Salud Mental
    Monterrey, 64710, Mexico
  • Consultorio Especializado Psiquiatría Infantil y Adolescentes
    San Luis Potosí, 78200, Mexico
  • West Visayas State University Medical Center
    Iloilo City, 5000, Philippines
  • National Center for Mental Health
    Mandaluyong City, 1553, Philippines
  • Veterans Memorial Medical Center
    Quezon City, 1101, Philippines
  • NZOZ Poradnia Zdrowia Psychicznego
    Kobierzyce, 55-040, Poland
  • Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu
    Torun, 87-100, Poland
  • Instytut Psychiatrii i Neurologii
    Warsawa, 02-957, Poland
  • INSPIRA Clinical Research
    San Juan, 00918, Puerto Rico
  • RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU
    Ivano Frankivsk, 76014, Ukraine
  • SI Institute of Neurology, Psychiatry and Narcology of NAMSU
    Kharkiv, 61068, Ukraine
  • SI Institute of Children and Adolescents Healthcare of NAMSU
    Kharkiv, 61153, Ukraine
  • CI Kherson Regional Psychiatric Hospital of Kherson RC
    Kherson, 73488, Ukraine
  • CI Lviv Regional Clinical Psychiatric Hospital
    Lviv, 79021, Ukraine
  • CI Odesa Regional Medical Center of Mental Health
    Odesa, 65006, Ukraine
  • O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy
    Poltava, 36006, Ukraine
  • Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU
    Ternopil, 46020, Ukraine
  • Chair of Psychiatry and Narcology, Vinnytsia National Medical University, O.I. Yushchenko Regional Psychoneurological Hospital
    Vinnytsia, 21005, Ukraine
09

References and documents

Publications

  • DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. J Am Acad Child Adolesc Psychiatry. 2017 Dec;56(12):1015-1025. doi: 10.1016/j.jaac.2017.10.006. Epub 2017 Oct 13. PubMed 29173735 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Jan 27, 2014
Start
Mar 2014
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results first posted
Dec 20, 2017
Last update
Dec 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02046369
Responsible party
Sponsor
First posted
Jan 27, 2014
Start date
Mar 2014
Primary completion
Oct 2016
Completion
Oct 2016
Results posted
Dec 20, 2017
Last update
Dec 20, 2017

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion